3-Me-PCE
Appearance
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
3D model (JSmol) | |
| |
|
3-Me-PCE is the 3-methyl derivative of the internationally controlled substance Eticyclidine (PCE). It shares structural similarities with 3-MeO-PCE and 3-HO-PCE. 3-Me-PCE first appeared in the scientific literature in 2015 in the context of synthesis and analytical caracterization of a series of arylcyclohexylamines by Wallach et al. It is believed to produce ketamine-like dissociative effects predominantly via antagonism of NMDA receptors.[1] Anecdotal evidence of its efficacy dates back to 2022 and assigns it a potency similar to other PCE analogs.[2] The EUDA issued a notification of its first analytical identification in March 2024.[3]
See also
[edit]References
[edit]- ^ Wallach J, Colestock T, Cicali B, Elliott SP, Kavanagh PV, Adejare A, et al. (2016). "Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines". Drug Testing and Analysis. 8 (8): 801–815. doi:10.1002/dta.1861. ISSN 1942-7611. PMID 26360516.
- ^ "3-Me-PCE - Erowid Exp - 'The Electric Fog'". www.erowid.org. Archived from the original on 2023-09-08. Retrieved 2025-06-08.
- ^ "EU Early Warning System Formal Notification: N‑ethyl‑1‑(3‑methylphenyl)cyclohexan‑1‑amine (3‑Me‑PCE)" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 11 March 2024. Retrieved 9 June 2025.